The lack of an effective, detailed workup algorithm for positive results in multicenter lung cancer screening trials results in a lower cancer yield from invasive procedures and later diagnoses for participants, according to a new study presented at the RSNA meeting.
The lack of an effective, detailed workup algorithm for positive results in multicenter lung cancer screening trials results in a lower cancer yield from invasive procedures and later diagnoses for participants, according to a new study presented at the RSNA meeting.
During a scientific session on Wednesday afternoon, Dr. David Yankelevitz, investigator in the New York Early Lung Cancer Action Program (NY-ELCAP), compared
workup algorithms and results for the New York trial and the Lung Screening Study (LSS), the pilot study of the National Lung Cancer Screening Study.
In NY-ELCAP, with 6295 participants at risk for lung cancer, a very detailed algorithm was used following diagnosis with CT. In contrast, the LSS, which randomized patients to CT or x-ray, did not specify an algorithm as organizers determined that they could not dictate medical practice. Yankelevitz's study analyzed results for 1586 participants in the LSS's CT-arm.
Participants in the two studies were at similar risk for lung cancer, had the same initial baseline test, and had an annual repeat test.
In the NY-ELCAP, 92% of invasive procedures prompted by the baseline study were positive. Invasive procedures prompted by the annual repeat exam were also positive in 92% of cases. By comparison, in LSS participants, 57% of invasive procedures prompted by the baseline study were positive, and 44% of those prompted by the annual repeat exam were positive.
At baseline in both studies, cancers were detected at larger sizes, as expected.
However, the size of cancers detected at annual repeat differed markedly, as 55% were smaller than 10 mm in the NY-ELCAP study, whereas only 13% were smaller than 10 mm for LSS.
Researchers also noted that the percent of cancers detected at stage 1 was higher in the New York study relative to the LSS.
Outcomes were better in the NY-ELCAP study most likely due to differences in the workup algorithms, according to Yankelevitz, a professor of radiology at Weill Cornell Medical College.
"This study shows the benefit of workup algorithms in screening protocols. Screening is not just about the initial test, it includes the baseline screening test all the way through diagnostics, including pathology," he said in an interview with Diagnostic Imaging after the session.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New DEXA Scan Study Links Thyroid Medication Levothyroxine to Higher Bone Loss Risk in Seniors
November 25th 2024Use of the medication levothyroxine, commonly prescribed for hypothyroidism, was associated with greater long-term loss of total body bone mass in seniors, according to new DEXA research to be presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Is Contrast-Enhanced Mammography a Viable Option for Diagnosing Invasive Lobular Carcinoma?
December 15th 2023Contrast-enhanced mammography had a 98 percent sensitivity rate for diagnosing invasive lobular carcinoma and provided high conspicuity for 82 percent of detected lesions, according to research presented at the recent Radiological Society of North America (RSNA) conference.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.